Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis

Abstract

PurposeTo evaluate the association of serum levels of adipokines and cytokines with psoriasis.Materials and MethodsA comprehensive literature search was performed in PubMed, ScienceDirect and Web of Science for the available relevant studies published before December 1, 2016. Differences in serum marker levels between patients and controls were pooled as standardized mean differences (SMDs) with 95% confidence interval to combine the effect estimations. We also conducted stratified analysis, meta-regression analysis and sensitivity analysis.ResultsSixty-three studies containing 2876 psoriasis patients and 2237 healthy controls were included in this meta-analysis. The pooled serum levels of TNF-α, IFN-γ, IL-2, IL-6, IL-8, IL-18, IL-22, chemerin, lipocalin-2, resistin, sE-selectin, fibrinogen and C3 were higher in psoriasis patients compared with healthy controls (all P < 0.05). In contrast, adiponectin levels were lower. Serum levels of IL-1β, IL-4, IL-10, IL-12, IL-17, IL-21, IL-23, visfatin and omentin were not significantly different between psoriasis patients and controls (all P > 0.05). However, increased serum levels of IL-17 correlated with psoriasis in men. For other biomarkers, age, gender and psoriasis area and severity index did not explain the differences in effect size between the studies.ConclusionsSerum levels of TNF-α, IFN-γ, IL-2, IL-6, IL-8, IL-18, IL-22, chemerin, lipocalin-2, resistin, sE-selectin, fibrinogen, complement 3, and adiponectin correlate with psoriasis and can be used as potential biomarkers for psoriasis and response to the treatment. Future studies are needed to identify additional players involved in the pathogenesis of psoriasis and to fully decipher the underlying mechanism.

Circulating CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood‐Heat Syndrome and Blood‐Stasis Syndrome

“…We found lower IL-10 mRNA levels in PBMCs of psoriasis patients when compared to healthy controls, especially in psoriatic BS syndrome patients, in disagreement with the elevated fraction of CD14 + HLA-DR −/low MDSC/ CD14 + cells. Most publications have described that IL-10 levels are decreased in the patient serum [39], but some authors have also reported that IL-10 serum levels were not changed in psoriasis [40], which is in line with our data. A possible cause of our results may be that MDSCs induce a 1/ 2 imbalance in psoriasis patients under specific conditions, such as the stationary clinical stage of psoriasis (psoriatic BS syndrome).…”

Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment

“…Other experimental models function via induction of elevated levels of dermal IL-23, which in turn activates IL-23R-expressing dermal lymphocytes including γδ17 cells, αβ T cells, and ILCs. This may be achieved directly by intradermal injection of IL-23 (Gauld et al, 2018;Rizzo et al, 2011), or via increased systemic levels of IL-23 (Leys et al, 2019), although human psoriasis is not usually accompanied by increased serum levels of IL-23 (Bai et al, 2017). The most widely used experimental model is topical application of the TLR7/8 agonist imiquimod (Aldara; Gilliet et al, 2004;van der Fits et al, 2009), which induces the innate activation of dermal DCs (van der Fits et al, 2009).…”

Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis

“…the appearance of skin lesions after skin trauma [3,4]. Most previous studies have reported increased serum IL-6 concentrations in patients with psoriasis, particularly in those with active disease [3,[6][7][8][9][10][11][12][13][14][15]. The concentration of IL-6 in serum might be related to the severity of both psoriatic skin lesions and joint involvement.…”